RBC Capital downgrades Chemours and cuts price target amid titanium dioxide weakness
RBC Capital lowered Chemours' rating to Sector Perform from Outperform and reduced its price target to $14.00 from $22.00. The downgrade cited persistent weakness in titanium‑dioxide demand and headwinds in the refrigerants business. RBC also trimmed its third‑quarter fiscal 2026 EBITDA estimate to $185 million from $187 million and its fiscal‑2026 and fiscal‑2027 EBITDA forecasts to $760 million and $900 million, respectively, down from $780 million and $925 million.
Why it matters
The lower price target and reduced EBITDA forecasts may pressure Chemours' share price, as investors adjust expectations for near‑term earnings. RBC’s view that the stock is fully valued at current levels reinforces the downside bias.
Key facts
- 1RBC Capital downgraded Chemours to Sector Perform from Outperform. investing.com
- 2RBC cut Chemours' price target to $14.00 from $22.00. investing.com
- 3RBC lowered the third‑quarter fiscal 2026 EBITDA estimate to $185 million from $187 million. investing.com
- 4RBC lowered the fiscal‑2026 EBITDA forecast to $760 million from $780 million. investing.com
- 5RBC lowered the fiscal‑2027 EBITDA forecast to $900 million from $925 million. investing.com
- 6Chemours shares fell about 2.5% in pre‑market trading after the downgrade. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.